中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (14): 2052-2058.doi: 10.3969/j.issn.2095-4344.2016.14.011

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

大黄素对骨髓间充质干细胞移植治疗缺血性再灌注肾损伤的影响

李 忠   

  1. 南阳理工学院张仲景国医学院,河南省南阳市 473004
  • 收稿日期:2016-02-28 出版日期:2016-04-01 发布日期:2016-04-01
  • 作者简介:李忠,女,1970年生,河南省南阳市人,汉族,2015年河南大学医学院毕业,硕士,副教授,主要从事中医内科结合基础医学研究。

Emodin effects on renal ischemia/reperfusion injury after bone marrow mesenchymal stem cell transplantation

Li Zhong   

  1. Zhang Zhongjing College of Traditional Chinese Medicine, Nanyang Institute of Technology, Nanyang 473004, Henan Province, China
  • Received:2016-02-28 Online:2016-04-01 Published:2016-04-01
  • About author:Li Zhong, Master, Associate professor, Zhang Zhongjing College of Traditional Chinese Medicine, Nanyang Institute of Technology, Nanyang 473004, Henan Province, China

摘要:

文章快速阅读:

 

文题释义:
大黄素为蒽醌类衍生物,是中药大黄的主要有效成分,其药理作用与大黄有许多相似之处,具有诸多药理学作用:抑制胰酶活性、抗炎、抑菌、免疫调节、保护肝肾、利胆、抗氧化、清除自由基、抑制血小板聚集、改善微循环、降低血液黏度、抗肿瘤等。
肿瘤坏死因子肾缺血再灌注损伤发生后,机体单核、巨噬系统被过度激活,肿瘤坏死因子mRNA表达明显增高,产生大量肿瘤坏死因子,肿瘤坏死因子是激活的巨噬细胞杀灭病原微生物及肿瘤细胞的主要效应分子,也是重要的炎性递质,在炎症的发生发展中起着多种作用。
 
背景:已有研究表明大黄素通过抑制炎症因子释放对肠缺血再灌注损伤具有保护作用。
目的:探讨大黄素对骨髓间充质干细胞移植治疗缺血性再灌注肾损伤的作用。
方法:40只SD大鼠随机分为5组(n=8):假手术组、缺血再灌注组、骨髓间充质干细胞组、大黄素低剂量干预组、大黄素高剂量干预组。除假手术组外,其余4组建立大鼠肾缺血再灌注损伤模型。造模后骨髓间充质干细胞组下腔静脉注射1 mL骨髓间充质干细胞悬液,大黄素低剂量干预组与高剂量干预组术前7 d内每天灌胃大黄素30 mg/kg和60 mg/kg,后续处理与骨髓间充质干细胞组一致。再灌注6 h后,苏木精-伊红染色法检测肾组织病理改变,实时荧光定量PCR检测肿瘤坏死因子α,白细胞介素6和白细胞介素18以及TLR2和TLR4 mRNA表达水平,免疫印迹法检测COX-2,ICAM-1,iNOS蛋白表达水平。
结果与结论:①缺血再灌注后可见大量小管上皮脱落,间质有炎性细胞浸润;骨髓间充质干细胞组可见部分小管上皮细胞脱落,部分间质有炎细胞浸润;药物低剂量干预组与高剂量干预组肾小管管腔几乎完整,少量间质有炎细胞浸润;②与假手术组相比,缺血再灌注组肿瘤坏死因子α,白细胞介素6,白细胞介素18以及TLR2,TLR4 mRNA表达水平显著升高(P < 0.05),COX-2,ICAM-1,iNOS蛋白表达水平也显著升高(P < 0.05);骨髓间充质干细胞组上述各因子表达明显低于缺血再灌注组(P < 0.05);大黄素低剂量干预组与高剂量干预组的降低程度更为显著,且与大黄素剂量相关;③结果表明,大黄素具有促进骨髓间充质干细胞改善大鼠缺血性再灌注肾损伤的作用。

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程 
 
ORCID: 0000-0003-0580-9987(李忠)

关键词: 干细胞, 移植, 大黄素, 骨髓间充质干细胞, 缺血性再灌注肾损伤, 肿瘤坏死因子α, 白细胞介素6, 白细胞介素18, TLR2, TLR4, COX-2, ICAM-1, iNOS

Abstract:

BACKGROUND: Studies have shown that emodin protects against intestinal ischemia-reperfusion injury by inhibiting the release of inflammatory factors.

OBJECTIVE: To investigate the effect of emodin on renal ischemia/reperfusion injury after bone marrow mesenchymal stem cell transplantation.
METHODS: Forty Sprague-Dawley rats were randomized into five groups (n=8 per group): sham group, model group (renal ischemia/reperfusion injury group), bone marrow mesenchymal stem cell group (cell transplantation group), low-dose emodin group, high-dose emodin group. Rats in the latter four groups were pretreated with or without different concentrations (30 and 60 mg/kg) of emodin for 7 days, and then were subjected to clamping bilateral renal pedicles for 45 minutes, followed by injection of 1 mL bone marrow mesenchymal stem cell suspension. Six hours after reperfusion, the pathological changes of renal tissues were examined by hematoxylin-eosin staining; the mRNA levels of tumor necrosis factor α, interleukin-6, interleukin-18, TLR2 and TLR4 detected by real-time fluorescence quantitative PCR; and the protein expression of COX-2, ICAM-1 and iNOS determined by western blot.
RESULTS AND CONCLUSION: Compared with the sham group, rats in the model group showed obvious features of severe acute tubular damage and inflammatory cell infiltration. In the cell transplantation group, tubular epitheliael cells were partially lost with some inflammatory cells infiltrated in the renal interstitium. In the emodin groups, the tubular lumen was practically intact with little renal interstitial inflammatory cells. Compared with the sham group, a significant increase in the mRNA levels of tumor necrosis factor α, interleukin-6, interleukin-18, TLR2 and TLR4 as well as in the protein levels of COX-2, ICAM-1 and iNOS was found in the model group (both P < 0.05). However, bone marrow mesenchymal stem cell transplantation attenuated this ischemia/reperfusion-induced increase in the expression of the above-mentioned factors (P < 0.05). Furthermore, the effects of bone marrow mesenchymal stem cell transplantation were further augmented by pretreatment with emodin in a dose-dependent manner. These findings suggest that emodin can enhance the protective effects of bone marrow mesenchymal stem cells on renal ischemia/reperfusion injury.
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程 

Key words: Bone Marrow, Mesenchymal Stem Cell Transplantation, Reperfusion Injury, Kidney, Emodin, Tissue Engineering